A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome

Sabrina Bondu Anne-Sophie Alary 1 Carine Lefevre 2 Alexandre Houy 3 Grace Jung 4 Thibaud Lefebvre 5 David Rombaut Ismael Boussaid Abderrahmane Bousta François Guillonneau 6 Prunelle Perrier Samar Alsafadi Michel Wassef 7 Raphael Margueron 8 Alice Rousseau 9 Nathalie Droin 10 Nicolas Cagnard 11 Sophie Kaltenbach 12 Susann Winter Anne-Sophie Kubasch Didier Bouscary 13 Valeria Santini Andrea Toma 14 Mathilde Hunault 15 Aspasia Stamatoullas 16 Emmanuel Gyan 17 Thomas Cluzeau 18 Uwe Platzbecker 19 Lionel Ades 20 Hervé Puy 21 Marc-Henri Stern 22 Zoubida Karim 23 Patrick Mayeux 13 Elizabeta Nemeth 24 Sophie Park 25 Tomas Ganz 24 Léon Kautz 26 Olivier Kosmider 13 Michaela Fontenay 13
Abstract : Myelodysplastic syndromes (MDS) with ring sideroblasts are hematopoietic stem cell disorders with erythroid dysplasia and mutations in the SF3B1 splicing factor gene. Patients with MDS with SF3B1 mutations often accumulate excessive tissue iron, even in the absence of transfusions, but the mechanisms that are responsible for their parenchymal iron overload are unknown. Body iron content, tissue distribution, and the supply of iron for erythropoiesis are controlled by the hormone hepcidin, which is regulated by erythroblasts through secretion of the erythroid hormone erythroferrone (ERFE). Here, we identified an alternative ERFE transcript in patients with MDS with the SF3B1 mutation. Induction of this ERFE transcript in primary SF3B1-mutated bone marrow erythroblasts generated a variant protein that maintained the capacity to suppress hepcidin transcription. Plasma concentrations of ERFE were higher in patients with MDS with an SF3B1 gene mutation than in patients with SF3B1 wild-type MDS. Thus, hepcidin suppression by a variant ERFE is likely responsible for the increased iron loading in patients with SF3B1-mutated MDS, suggesting that ERFE could be targeted to prevent iron-mediated toxicity. The expression of the variant ERFE transcript that was restricted to SF3B1-mutated erythroblasts decreased in lenalidomide-responsive anemic patients, identifying variant ERFE as a specific biomarker of clonal erythropoiesis.
Complete list of metadatas

Contributor : Zoubida Karim <>
Submitted on : Wednesday, November 6, 2019 - 11:06:44 AM
Last modification on : Friday, November 8, 2019 - 10:48:05 AM



Sabrina Bondu, Anne-Sophie Alary, Carine Lefevre, Alexandre Houy, Grace Jung, et al.. A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome. Science Translational Medicine, American Association for the Advancement of Science, 2019, 11 (500), pp.eaav5467. ⟨10.1126/scitranslmed.aav5467⟩. ⟨hal-02350931⟩



Record views